Oral Zn-Telomir for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new pill, Zn-Telomir, for people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery and has gotten worse after previous treatments. The goal is to see if this drug can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer confirmed by biopsy.
- Your cancer is advanced (has spread) or cannot be removed by surgery.
- You have already tried at least one systemic treatment for advanced disease and it stopped working.
- You have at least one measurable tumor.
- You are 18 years or older.
- If you can get pregnant or father a child, you must agree to use highly effective birth control during treatment and for 3 months after.
- You have not had anticancer therapy in the last 28 days.
- You are expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Hear when a new Advanced Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.